Down-regulating autoimmune regulator (AIRE) function in B cells to produce antibodies is described. The antibodies can be class-switched, high affinity, and neutralizing, and have a high degree of somatic hypermutations, even in the framework region, as compared to antibodies produced in the absence of AIRE downregulation.

The present invention relates to combination therapies with anti-CD38 antibodies.

Described herein are engineered antigen presenting cells that can be capable of modulating a target T-cell in a T-cell antigen specific manner. In some embodiments, the engineered APCs can include a modified antigen presentation pathway. Also described herein are methods of making and using the engineered antigen presenting cells.

The present invention provides fusion polypeptides comprising an anti-CD40 scFv and IL-21. Also provided are methods for making and using the fusion polypeptides for the generation of B regulatory cells (B.sub.regs), and methods of treatment using said B.sub.regs.

Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated B lymphocyte cell line. An isolated cell line includes an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin reactive to a first antigen and at least one endogenous secreted immunoglobulin reactive to a second antigen.

In one aspect, a method of treating cancer in a mammal is provided. The method comprises administering to the mammal an oncolytic vector that expresses a tumour antigen to which the mammal has a pre-existing immunity. In another aspect, a method of boosting immune response in a mammal having a pre-existing immunity to an antigen is provided comprising intravenous administration to the mammal of a B-cell infecting vector that expresses the antigen.

The disclosed method provides a direct method for creating immunological memory against HIV by educating a patient's naive T and B lymphocytes in vitro into HIV antigen-specific adaptive immune memory lymphocytes. Said memory lymphocytes which were created in vitro undergo process wherein memory B lymphocytes are genetically modified for broadly neutralizing antibodies, as well as repeatedly stimulated with HIV antigens. Memory T lymphocytes undergo gene editing for chemokine receptors used by HIV for infection. Said memory lymphocytes are administered to said patient with an immunological memory against HIV in a solution which does not contain chemicals that are opposed to anti-vaccine supporters.

The disclosed method provides an alternative approach of preventative vaccination which consists primarily of extracting and purifying monocytes, naive T and B lymphocytes from a patient and educating said lymphocytes against a pathogen in vitro until a population of antigen-specific memory lymphocytes are created with a memory against an infectious agent. Said memory lymphocytes are administered to a subject in a solution which consist primarily of blood plasma derived from said subject. In embodiments, one will see a vaccine approach wherein said vaccine excludes the inoculation of attenuated or killed whole pathogens, where inoculation of said vaccine does not illicit an immune response upon inoculation, and where said vaccine excludes chemicals such as thimerosal, formaldehyde, and aluminum which is all shunned by anti-vaccinators.

In certain embodiments, this disclosure relates to conjugates comprising a polypeptide of GM-CSF and a polypeptide IL-4. Typically, the GM-CSF and IL-4 are connected by a linker, e.g., polypeptide. In certain embodiments, the disclosure relates to isolated nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such nucleic acids.

In one aspect, a method of treating cancer in a mammal is provided. The method comprises administering to the mammal an oncolytic vector that expresses a tumor antigen to which the mammal has a pre-existing immunity. In another aspect, a method of boosting immune response in a mammal having a pre-existing immunity to an antigen is provided comprising intravenous administration to the mammal of a B-cell infecting vector that expresses the antigen.